Asset Details
Do you wish to reserve the book?
The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours
Do you wish to request the book?
The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours
2025
Overview
The most recent WHO classification of endocrine and neuroendocrine tumours has brought about significant changes in the diagnosis and grading of these lesions. For instance, pathologists now have the ability to stratify subsets of thyroid and adrenal neoplasms using various histological features and composite risk assessment models. Moreover, novel recommendations on how to approach endocrine neoplasia involve additional immunohistochemical analyses, and the recognition and implementation of these key markers is essential for modernising diagnostic capabilities. Additionally, an improved understanding of tumour origin has led to the renaming of several entities, resulting in the emergence of terminology not yet universally recognised. The adjustments in nomenclature and prognostication may pose a challenge for the clinical team, and care providers might be eager to engage in a dialogue with the diagnosing pathologist, as treatment guidelines have not fully caught up with these recent changes. Therefore, it is crucial for a surgical pathologist to be aware of the knowledge behind the implementation of changes in the WHO classification scheme. This review article will delve into the most significant diagnostic and prognostic changes related to lesions in the parathyroid, thyroid, adrenal glands and the gastroenteropancreatic neuroendocrine system. Additionally, the author will briefly share his personal reflections on the clinical implementation, drawing from a couple of years of experience with these new algorithms.
Publisher
BMJ Publishing Group Ltd and Association of Clinical Pathologists,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Adrenal Gland Neoplasms - classification
/ Adrenal Gland Neoplasms - diagnosis
/ Adrenal Gland Neoplasms - pathology
/ Biomarkers, Tumor - analysis
/ Endocrine Gland Neoplasms - classification
/ Endocrine Gland Neoplasms - diagnosis
/ Endocrine Gland Neoplasms - pathology
/ Humans
/ Mutation
/ Neuroendocrine Tumors - classification
/ Neuroendocrine Tumors - diagnosis
/ Neuroendocrine Tumors - pathology
/ Pancreatic Neoplasms - classification
/ Pancreatic Neoplasms - diagnosis
/ Pancreatic Neoplasms - pathology
/ Patients
/ Review
/ thyroid
/ Thyroid Neoplasms - classification
/ Thyroid Neoplasms - diagnosis
/ Thyroid Neoplasms - pathology
/ update
/ WHO
